Biotech Startups

Viatris is a healthcare company that develops and supplies medicines, including affordable generics and branded therapies, aiming for reliable supply of needed treatments. It serves patients and healthcare systems across the pharmaceutical industry.

1 investor

Vibrant Therapeutics develops multispecific antibody-based prodrugs with conditional activation and targeted delivery for patients with oncological, autoimmune, and neurological diseases. It runs computational drug discovery platforms (BumbleBee, LogicBee, NeuroBee) that combine proteomics analysis and antibody engineering to design biotherapeutics.

1 investor

Vicore Pharma is a clinical-stage biopharmaceutical company developing disease-modifying treatments for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis. The company's lead program, buloxibutid, is an oral small molecule in Phase 2b clinical trials.

1 investor

Clinical-stage developer of biologic therapies for inflammatory and autoimmune conditions

1 investor

The Global Alzheimer's Platform Foundation is a nonprofit organization that reduces the time and cost of clinical trials for Alzheimer's and Parkinson's disease by coordinating multi-site research networks and providing trial management, data, and participant recruitment services. It serves pharmaceutical sponsors, contract research organizations, and clinical research sites seeking to accelerate neurodegenerative disease drug development.

1 investor

Developer of a novel therapeutic for metastatic melanoma (exited).

1 investor

Viking Therapeutics is a clinical-stage biopharmaceutical company developing therapies in areas such as metabolic and endocrine disorders. This page presents its board of directors.

1 investor

VintaBio provides viral vector manufacturing for clinical and commercial gene therapies, using a single-stream process (VintaProcess) to produce high-yield, high-purity vectors. It offers end-to-end services from discovery through final delivery for cell and gene therapy developers.

1 investor

Viralgen provides contract manufacturing services for AAV-based gene therapy, supporting early-phase preclinical and clinical production with a platform designed for regulatory compliance and batch scalability. The company serves gene therapy developers pursuing treatments for rare diseases.

1 investor

Viramal develops proprietary products for women's sexual, vaginal, and reproductive health using its Fem Med Tech platform. The company targets unmet needs in women's healthcare through a clinically-led approach.

1 investor

Virchu operates a histopathology-powered precision oncology platform that aggregates de-identified whole-slide images and longitudinal patient data to train and validate AI models for cancer detection and treatment. The platform serves oncology researchers and AI developers seeking curated, representative data across multiple cancer types.

1 investor

Virica is a biotech company that develops small-molecule "Viral Sensitizers" which temporarily reduce host cell defenses during viral vector production to increase yield, quality, and scalability. Its technology serves cell and gene therapy and vaccine manufacturers seeking to improve manufacturing productivity and reduce costs.

1 investor

Viridaxis produces parasitoids for organic and integrated crop protection, serving agricultural customers seeking sustainable pest management solutions. The company invests in research and development to improve agricultural sustainability.

1 investor

Virilitas Labs develops research-led technologies focused on male fertility and reproductive health, drawing on over 20 years of study in reproduction and genetics. It aims to translate scientific research into products supporting couples with male infertility challenges.

1 investor

Viriom Inc. develops a pipeline of treatments for infectious diseases (blood-borne and respiratory viral diseases) and malignant diseases (solid tumors) through a global drug development platform built with partner networks. The company aims to broaden access to new therapies in both developed and developing countries.

1 investor

Virogin develops oncolytic virus therapies and mRNA vaccines for cancer treatment, combining immunotherapy approaches to create immuno-oncology therapeutics for patients with serious cancers.

1 investor

Mid-stage drug developer of botanical anti-viral topical prescription candidates for skin diseases; acquired by TFS Corporation in 2017.

1 investor

Virtuoso Therapeutics is an oncology-focused biotech developing novel bispecific antibody therapies aimed at addressing challenges like efficacy and therapeutic window. It operates a hybrid US-China model for virtual R&D, drawing on science and talent from both regions.

1 investor

Developing therapeutics, including gene therapy, for dry Age-Related Macular Degeneration.

1 investor

VisiCELL Medical develops MRI-based in vivo imaging analytics to track therapeutic cells in the body for cell therapy developers working in oncology, autoimmune disease, and regenerative medicine. Its tools are designed to support cell therapy development across the preclinical-to-clinical continuum, providing insight into treatment efficacy.

1 investor

Mattek develops human-relevant in vitro research products, including lab-grown 3D human epithelial tissue models, banks of primary human cells, and cell culture dishes and plates optimized for cell growth and imaging. It serves life science researchers studying clinical outcomes through ethical, human-relevant alternatives.

1 investor

VistaGen Therapeutics develops intranasal pherine compounds targeting neuropsychiatric and women's health conditions through a mechanism that activates nasal sensory neurons to modulate brain circuits without systemic absorption. The company's pipeline includes fasedienol in Phase 3 trials for acute social anxiety disorder, along with earlier-stage candidates for depression, menopausal hot flashes, mental fatigue, and cancer cachexia.

1 investor

VistaraBio provides research tools and services for drug discovery, including modified protein assays, post-translationally modified protein catalogs, and cell screening platforms using bioactive peptides. The company serves pharmaceutical and biotech researchers developing small molecule and protein degrader therapeutics.

1 investor

Vita Partners provides investment management, asset management, and project and construction management for life sciences, R&D, and innovation real estate, delivering facilities such as biologics, vaccine, pharmaceutical, and R&D plants. It serves real estate partners and clients across the APAC region, with projects in Singapore, China, Malaysia, Japan, and other markets.

1 investor